pharmaphorum

JANUARY 17, 2022

After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Partnering with EraCal builds upon the success of Novo Nordisk’s Wegovy (semaglutide) chronic weight management drug, which was approved by the FDA in June 2021.

FDA Approval 123

FDA Approval In-Vitro Regulation Hormones 123

The Pharma Data

APRIL 28, 2023

FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya ® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5

Hormones 40

Hormones FDA Approval In-Vivo Production 40

The Pharma Data

DECEMBER 18, 2020

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer. Food and Drug Administration (FDA) has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. BASEL, Switzerland, Dec. Indication.

Hormones 52

Hormones FDA Approval Containment Medicine 52

XTalks

JANUARY 16, 2025

It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone. It will rival Amgens Tepezza (teprotumumab-trbw), which became the first approved treatment for thyroid eye disease with its FDA approval in 2020.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JUNE 29, 2023

This episode features an interview with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma, about the recent FDA approval of the company’s drug Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause.

Life Science 52

Life Science Hormones FDA Approval Development 52

Pharmaceutical Technology

MARCH 7, 2023

Medical interventions typically recommended during this stage include drugs to treat depression and hormone replacement therapies (HRT). Science drives new developments in medications Specific drug-based treatments for symptoms of anxiety and depression during perimenopause are largely unexamined.

Hormones 130

Hormones Scientist Drugs Research 130

XTalks

APRIL 29, 2022

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 agonists were first developed as diabetes treatments.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Pharmaceutical Technology

OCTOBER 13, 2022

The drug won its original FDA approval in May last year to treat heavy menstrual bleeding that accompanies uterine fibroids in premenopausal women. In August this year, it gained a second FDA endorsement to treat moderate to severe endometriosis.

Hormones 130

Hormones FDA Approval Drugs Marketing 130

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide.

HR 162

HR Marketing Hormones FDA Approval 162

XTalks

JULY 17, 2024

Sweden-based biotech Camurus shared positive Phase III trial data for CAM2029, one of its lead candidates, in patients with the rare hormonal disorder acromegaly. Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Lerner researchers developed a novel artificial intelligence platform to identify potential drugs for COVID-19, finding melatonin to be a promising candidate.

Research 98

Research Hormones Protein Regulation 98

The Pharma Data

NOVEMBER 21, 2021

The FDA approved Voxzogo under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate or intermediate clinical endpoint. 3] Achondroplasia is caused by mutations in the FGFR3 gene. Inheritance is autosomal dominant.[1][2]

FDA Approval 52

FDA Approval Drugs Regulation Genetics 52

The Pharma Data

SEPTEMBER 1, 2021

The FDA approval of INVEGA HAFYERA™ is based on the results of a 12-month, randomized, double-blind, non-inferiority Phase 3 global study that enrolled 702 adults (ages 18-70) living with schizophrenia from 20 countries. Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC.

FDA Approval 52

FDA Approval Medicine Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 10, 2021

Related: GSK’s Dostarlimab Wins FDA Approval for dMMR Endometrial Cancer. It was developed based on Nobel Prize-winning findings of how cells sense and adapt to oxygen availability. Kidney dysfunction in CKD leads to impaired production of the hormone, particularly in more advanced disease. What is Daprodustat?

Trials 97

Trials Hormones Drugs FDA Approval 97

XTalks

AUGUST 22, 2024

Yorvipath (palopegteriparatide; TransCon PTH) has been approved to treat hypoparathyroidism, a rare endocrine disorder affecting 70,000 to 90,000 people in the US. Yorvipath, developed using Ascendis Pharma’s TransCon technology, is the first and only approved treatment for hypoparathyroidism, marking this approval as a major milestone.

Hormones 52

Hormones FDA Approval Trials Clinical Trials 52

pharmaphorum

JANUARY 26, 2023

Merck has said it will abandon the KEYNOTE-991 study of PD-1 inhibitor Keytruda (pembrolizumab) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) after it showed no benefit on either overall survival (OS) or radiographic progression-free survival (rPFS) when the data was analysed midway though.

Hormones 59

Hormones Trials FDA Approval Clinical Development 59

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. Pharma, a frontrunner in cannabinoid-derived drug discovery and development is developing CAUMZ for the treatment of cancer cachexia patients shortly.

Marketing 94

Marketing Pharma Companies Development Hormones 94

Delveinsight

AUGUST 31, 2021

FDA’s Green Flag to Ascendis’s Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency. Growth Hormone Deficiency , commonly known as dwarfism, can constitute short stature and complications with metabolism, which arise due to inadequate production of growth hormones by the pituitary gland inside the body.

Hormones 60

Hormones FDA Approval Development Drugs 60

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa. and CHICAGO , Oct.

FDA Approval 40

FDA Approval Hormones Production Drugs 40

pharmaphorum

OCTOBER 26, 2022

Those who develop psoriatic arthritis are saddled with joint pain and inflammation. Food and Drug Administration approved Vtama (tapinarof) cream, an aryl hydrocarbon receptor agonist and the first FDA-approved steroid-free topical medication in its class. When this hormone is suppressed, response to stressors (e.g.

Hormones 98

Hormones FDA Approval Doctors Doctor 98

XTalks

FEBRUARY 3, 2023

Until now, fulvestrant was the only other selective estrogen receptor degrader (SERD) therapy approved for ER+ breast cancer, delivered via intramuscular injections. This approval follows the promising results of the Phase III EMERALD global clinical trial published in the Journal of Clinical Oncology.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

pharmaphorum

OCTOBER 11, 2020

When added to standard treatment with hormone-based drugs, Ibrance (palbociclib) was unable to achieve better iDFS than hormone therapy alone in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early-stage breast cancer.

Trials 52

Trials HR Hormones Drugs 52

pharmaphorum

AUGUST 8, 2022

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ($3.1 billion) blockbuster. Most men with mHSPC will eventually progress to CRPC, which has poor survival prospects.

Sales 59

Sales Hormones Marketing FDA Approval 59

The Pharma Data

AUGUST 17, 2021

approval of pump use for Lilly’s novel insulin is latest development designed to help people with diabetes manage blood sugar levels. Lyumjev, a novel formulation of insulin lispro developed to speed the absorption of insulin into the bloodstream and reduce A1C levels, was approved by the FDA in June 2020.

Insulin 52

Insulin FDA Approval Doctors Doctor 52

pharmaphorum

DECEMBER 23, 2020

Originally developed to treat late-stage EGFR-mutated disease, the ADAURA study tested Tagrisso as an adjuvant treatment in patients with early disease following surgery. A molecule codenamed DNL151, currently in phase 1 development, has been selected to progress into late-stage clinical studies that are expected to begin in 2021.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 28, 2020

Shares in dermatology specialist Cassiopea, which is listed on the SWX exchange in Switzerland, rose almost 17% after news of the FDA approval emerged.

Dermatology 52

Dermatology Drugs Hormones FDA Approval 52

XTalks

FEBRUARY 7, 2023

The FDA approval is an important step forward for both women and men living with metastatic breast cancer, especially for those individuals whose tumor is no longer responding to endocrine-based therapies and who are facing a poor prognosis,” said Laura Carfang, executive director, SurvivingBreastCancer.org, in the press release.

HR 52

HR Hormones FDA Approval Antibody 52

XTalks

AUGUST 15, 2023

Akeega is a dual-action tablet (DAT) that contains the company’s androgen receptor-targeting hormone therapy Zytiga (abiraterone acetate) and PARP inhibitor (poly [ADP-ribose] polymerase inhibitor) niraparib. Lynparza received FDA approval in May 2020 for mCRPC in patients with homologous recombinational repair ( HRR ) gene mutations.

FDA Approval 52

FDA Approval Gene Hormones Drugs 52

XTalks

DECEMBER 22, 2021

The development and widespread adoption of new technologies is key to revolutionizing the way we diagnose, prevent, treat and manage disease. They can be developed and adapted quickly. This did the trick and set the stage for the development of viable mRNA-based therapeutics. RNA Therapeutics.

Life Science 98

Life Science RNA Vaccine Vaccination 98

XTalks

SEPTEMBER 17, 2020

While the table lists acceptable surrogate endpoints for trials of more common conditions, such as asthma, type 2 diabetes and various cancer types, the document also provides key information to developers of certain rare disease therapies. Both surrogate endpoints could be used to support traditional approval of a new drug or biologic.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

NOVEMBER 9, 2023

Eli Lilly is now fully armed on the GLP-1 front as it’s finally received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide), its obesity version of Mounjaro. The FDA approved Zepbound for chronic weight management in adults with obesity. Ozempic was approved in 2017 and Wegovy in 2021.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

SEPTEMBER 13, 2024

In a large-scale collaborative real-world study , HCA helped develop an algorithm-driven tool, tested across 82 hospitals, that reduced hospital outbreak sizes by 64 percent before the pandemic. Cigna (CI) Market Capitalization : $135.66 CVS Health (CVS) Market Capitalization : $95.74 McKesson (MCK) Market Capitalization : $89.78

Marketing 98

Marketing Pharmacy Gene Therapy Hormones 98

XTalks

FEBRUARY 21, 2024

There are currently no FDA-approved drug therapies for MASH, and the disease is characterized by excess fat accumulation and inflammation in the liver, which leads to liver scarring or fibrosis. There are on-going studies to develop formulations with extended duration of action.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

pharmaphorum

APRIL 1, 2022

And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko. With 34 approved biosimilars and dozens more in the pipeline, what does this year have in store? In September of 2021, the FDA approved Byooviz , which references Roche and Novartis’ blockbuster eye drug Lucentis.

Marketing 59

Marketing Pharmacy FDA Approval Manufacturing 59

The Pharma Data

DECEMBER 31, 2020

In mid-December, the FDA approved Orgovyx (relugolix), the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer. Orgovyx blocks the GnRH receptor and reduces production of testosterone, a hormone known to stimulate the growth of prostate cancer.

Vaccine 52

Vaccine Vaccination FDA Approval Hormones 52

XTalks

MARCH 8, 2024

Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications. According to the FDA, Jubbonti is approved for the same indications as Prolia, which include individuals at high risk for fracture including postmenopausal women with osteoporosis and men with osteoporosis.

Drugs 59

Drugs FDA Approval Production Immune Response 59